Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
MK-7762
- Development stage
- Phase 2
- Lead developer
- Gates Medical Research Institute
- Modality
- RNA-Targeting Small Molecules → Nucleic Acid-Directed Small Molecules → Small Molecules
- Administration
- Oral
01
Overview
MK-7762 is a synthetic oxazolidinone antibacterial agent under development for the treatment of tuberculosis (TB). It was discovered by Merck as part of the TB Drug Accelerator (TBDA) initiative and is being further developed in collaboration with the Bill & Melinda Gates Medical Research Institute. The drug acts as a protein synthesis inhibitor, specifically targeting the 50S ribosomal subunit of Mycobacterium tuberculosis, including strains resistant to current therapies. Preclinical studies indicate that MK‑7762 has improved selectivity and safety compared to linezolid, another oxazolidinone used in TB treatment, with reduced inhibition of mitochondrial protein synthesis and favorable pharmacokinetic properties suitable for once-daily dosing. As of mid‑2024, it has completed Phase I clinical trials evaluating its safety, tolerability, pharmacokinetics, and food effect in healthy volunteers[1][5][8].
- Other names
- MK 7762MK7762MK-7762TBD09TBD-09TBD 09
02
Targets
60S (Eukaryotic 60S ribosomal subunit)
Beyond the preview
Go deeper on MK-7762.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on MK-7762.